CLDI (Calidi Biotherapeutics) FCF Yield %: -605.93 (As of Jun. 24, 2026)


CLDI Calidi Biotherapeutics Inc CLDI
12 GF Score
Price $0.16
! 1 Warning Sign
View Full Analysis

What is Calidi Biotherapeutics FCF Yield %?

Calidi Biotherapeutics CLDI +0.64% 12 FCF Yield % is -605.93 as of Jun. 24, 2026. GuruFocus rates CLDI with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,417 Biotechnology companies, Calidi Biotherapeutics ranks worse than 98.45% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Calidi Biotherapeutics's Trailing 12-Month Free Cash Flow is $-18.40 Mil, and Market Cap is $3.04 Mil. Therefore, Calidi Biotherapeutics's FCF Yield % for today is -605.93%.

The historical rank and industry rank for Calidi Biotherapeutics's FCF Yield % or its related term are showing as below:

CLDI' s FCF Yield % Range Over the Past 10 Years
Min: -622.96   Med: 0   Max: 0
Current: -605.93

CLDI's FCF Yield % is ranked worse than
98.45% of 1417 companies
in the Biotechnology industry
Industry Median: -9.7 vs CLDI: -605.93

Calidi Biotherapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

Calidi Biotherapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Calidi Biotherapeutics FCF Yield % Related Terms

Calidi Biotherapeutics FCF Yield % Historical Data

* Premium members only.

The historical data trend for Calidi Biotherapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Calidi Biotherapeutics FCF Yield % Chart

Calidi Biotherapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Yield %
Get a 7-Day Free Trial 0.00 0.00 -616.79 -990.70 -253.59

Calidi Biotherapeutics Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -158.64 -248.70 -162.52 -240.32 -585.63

CLDI vs CMND, BIXT, GRI: FCF Yield % Comparison

For the Biotechnology subindustry, Calidi Biotherapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Calidi Biotherapeutics FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Calidi Biotherapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Calidi Biotherapeutics's FCF Yield % falls into.


CLDI
12GF Score
Calidi Biotherapeutics Inc CLDI
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Calidi Biotherapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Calidi Biotherapeutics's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-21.413 / 8.44389
=-253.59%

Calidi Biotherapeutics's annualized FCF Yield % for the quarter that ended in Mar. 2026 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-4.121 * 4 / 2.8147356
=-585.63%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -605.93 mean?
Calidi Biotherapeutics (CLDI) has a FCF Yield % of -605.93 as of Jun. 24, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Calidi Biotherapeutics and its competitors. According to the industry distribution chart, Calidi Biotherapeutics ranks #1395 out of 1417 companies in the Biotechnology industry, placing it in the top 98.4%.
Is Calidi Biotherapeutics' FCF Yield % too high?
Calidi Biotherapeutics' current FCF Yield % is -605.93. Based on the distribution chart, Calidi Biotherapeutics ranks #1395 out of 1417 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Calidi Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Calidi Biotherapeutics' FCF Yield % compare to CMND and BIXT?
According to the Biotechnology industry distribution chart, Calidi Biotherapeutics ranks #1395 out of 1417 companies for FCF Yield %. This places Calidi Biotherapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Calidi Biotherapeutics and its competitors. Calidi Biotherapeutics's current FCF Yield % is -605.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Calidi Biotherapeutics stock overvalued right now?
Calidi Biotherapeutics (CLDI) has a current FCF Yield % of -605.93. The current FCF Yield % is -605.93. Calidi Biotherapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Calidi Biotherapeutics (CLDI), the current FCF Yield % is -605.93 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Calidi Biotherapeutics Business Description

Address 4475 Executive Drive, Suite 200, San Diego, CA, USA, 92121
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
12GF Score

Get the complete analysis for CLDI

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.16
Price